Theodore W Randolph

This inventor holds 34 USPTO granted patents and 30 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Thermostable Vaccines. Top assignees: University of Colorado, Barofold, Inc., University Technology Corporation. Active years: 1990-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Theodore W Randolph. Retrieved from https://idiyas.com/inventor/theodore-w-randolph

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 30)

% Patents Active = 79.4

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 3.2

ph-index = 10

Forward Citations = 573(Granted Patents)

Location History:

Berkeley, CA (US) (1990)
Longmont, CO (US) (2006 - 2008)
Niwot, CO (US) (1998 - 2023)

Company Filing History:

20 out of 1,449

University of Colorado

University Technology Corporation

Becton Dickinson and Company Limited

University of California

patents

9. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1990-2025

Loading Chart...

Areas of Expertise:

Thermostable Vaccines

Immunogenic Formulations

Protein Refolding

Multi-Targeted Antigens

Adjuvant-Bound Vaccines

Pulmonary Administration

Monoclonal Antibodies

Dried Vaccine Compositions

Microparticles

Sustained-Release Compositions

Enzyme-Catalyzed Reactions

Pharmaceutical Solubilization

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12447127 - Thermostable vaccine compositions and methods of preparing the same (2025-10-21),

2. 12303602 - Compositions, methods and uses for thermally stable multi-targeted antigens (2025-05-20),

3. 12186384 - Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens (2025-01-07),

4. 12097291 - Thermostable vaccine compositions and methods of preparing same (2024-09-24),

5. 11806432 - Compositions, methods and uses for thermally stable multi-targeted antigens (2023-11-07),

6. 11491111 - Thermostable vaccine compositions and methods of preparing same (2022-11-08),

7. 11364293 - Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens (2022-06-21),

8. 11273127 - Compositions, methods and uses for thermally stable multi-targeted antigens (2022-03-15),

9. 10751408 - Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens (2020-08-25),

10. 8808710 - Method of preparing an immunologically-active adjuvant-bound dried vaccine composition (2014-08-19),

11. 8802828 - High pressure refolding of monoclonal antibody aggregates (2014-08-12),

12. 8710197 - High pressure refolding of protein aggregates and inclusion bodies (2014-04-29),

13. 8697848 - Method for reducing immunogenicity of therapeutic protein compositions (2014-04-15),

14. 8633034 - Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution (2014-01-21),

15. 8444991 - Method of preparing an immunologically-active adjuvant-bound dried vaccine composition (2013-05-21),

Certainly! Here is the article:

Title:

Theodore W Randolph: Pioneering Innovations in Vaccine Stability

Introduction:

Hailing from Niwot, CO, Theodore W Randolph is a prolific inventor with an impressive portfolio of 29 patents to his name. His groundbreaking work in developing thermally stable multi-targeted antigens has revolutionized the field of vaccine formulations and storage.

Latest Patents:

Randolph's latest patents showcase his expertise in creating innovative compositions and methods for thermally stable vaccines. One such patent focuses on the development of stabilized multimeric virus formulations, particularly targeting the human papillomavirus (HPV). His work includes lyophilizing HPV formulations to enhance stability and immunogenicity, as well as developing thermostable vaccine compositions containing volatile salts.

Career Highlights:

Throughout his career, Randolph has made significant contributions to the University of Colorado and Barofold, Inc. His research and inventions have played a crucial role in advancing vaccine technology, ensuring improved formulations and enhanced consistency in adjuvant distribution. Randolph's dedication to creating effective and stable immunogenic compositions has garnered him recognition as a leading figure in the field.

Collaborations:

In his endeavors, Randolph has collaborated with esteemed professionals such as John Frank Carpenter and Richard St John. Together, they have pushed the boundaries of vaccine development, working towards novel solutions for improving vaccine stability, storage, and efficacy.

Conclusion:

Theodore W Randolph stands as a trailblazer in the realm of vaccine innovation, consistently pushing the envelope with his pioneering research and patent developments. His dedication to advancing thermally stable vaccine formulations has not only transformed the field but also paved the way for more effective and accessible vaccination strategies.

Profile summary based on public USPTO records.